Screener
Relay Therapeutics, Inc. RLAY Q2 2026 earnings
Reported August 6, 2026 · After market close
Revenue$350.0KMiss by $610.0K
EPS-$0.41Miss by $0.02
Revenue estimate$960.0K
EPS estimate-$0.39
“This progress, including the ongoing Phase 3 trial in second-line breast cancer and the triplet combination work to support development in frontline breast cancer, reinforces the promise of mutant-selective PI3Kα inhibition and strengthens our confidence in zovegalisib's potential across multiple patient populations. Supported by a strong cash position with expected runway into 2029, we continue to focus on the execution of several clinical and regulatory milestones expected for zovegalisib this year as we work to develop potentially life-changing therapies for patients living with cancer and genetic disease.”
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$1.6M
EPS estimate-$0.40
Financials
Q2 2026Valuation & ratios
Versus estimates
Revenue
Q2 2026$350.0KMiss by $610.0K
Q1 2026$3.0MMiss by $2.6MQ4 2025$7.0MBeat by $2.0MQ2 2025$677.0KBeat by $662.7KQ1 2025$7.7MBeat by $3.9MDiluted EPS
FAQ
- When did Relay Therapeutics, Inc. report Q2 2026 earnings?
- Relay Therapeutics, Inc. (RLAY) reported Q2 2026 earnings on August 6, 2026 after market close.
- What were Relay Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Relay Therapeutics, Inc. reported revenue of $350.0K and eps of $-0.41 for Q2 2026.
- Did Relay Therapeutics, Inc. beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $960.0K by $610.0K. EPS missed the consensus estimate of $-0.39 by $0.02.
- How did Relay Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 48.3% from $677.0K a year earlier and eps grew 0.0% from $-0.41.
- Where can I find Relay Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-338013) and the 10-Q periodic report (0001193125-26-338056) directly on SEC EDGAR. The filing index links above go to sec.gov.
